In the present study, we developed a recombinant Smeg strain, rSmeg-hMIF-hIL-7 as a new anticancer therapeutic vaccine, expressing the chimeric fusion protein of h-MIF as the target Ag of the cancer vaccine and h-IL-7 as an adjuvant of the cancer vaccine to induce anti-MIF immune responses (graphical abstract). Here, MIF is linked to cancer.